Selective inhibition of STAT3 signaling using monobodies targeting the coiled-coil and N-terminal domains

Abstract

STAT3 is an attractive therapeutic target but its homology with other STAT proteins complicates the development of selective inhibitors. Here, the authors develop monobodies with high affinity and selectivity for STAT3 and show that they can interfere with cellular STAT3 activity.